BNP Paribas Arbitrage SA Raises Stake in XBiotech Inc (NASDAQ:XBIT)

BNP Paribas Arbitrage SA grew its stake in shares of XBiotech Inc (NASDAQ:XBIT) by 191.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,425 shares of the biopharmaceutical company’s stock after purchasing an additional 4,223 shares during the period. BNP Paribas Arbitrage SA’s holdings in XBiotech were worth $68,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Bank of Montreal Can boosted its position in shares of XBiotech by 31.8% during the 4th quarter. Bank of Montreal Can now owns 2,390 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 576 shares in the last quarter. Alliancebernstein L.P. boosted its position in shares of XBiotech by 11.7% during the 4th quarter. Alliancebernstein L.P. now owns 15,300 shares of the biopharmaceutical company’s stock worth $286,000 after purchasing an additional 1,600 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of XBiotech during the 4th quarter worth $40,000. Barclays PLC boosted its position in shares of XBiotech by 19.9% during the 4th quarter. Barclays PLC now owns 19,066 shares of the biopharmaceutical company’s stock worth $356,000 after purchasing an additional 3,161 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of XBiotech by 11.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 50,941 shares of the biopharmaceutical company’s stock worth $951,000 after purchasing an additional 5,176 shares in the last quarter. Institutional investors own 15.21% of the company’s stock.

Several equities research analysts recently commented on the stock. ValuEngine upgraded shares of XBiotech from a “sell” rating to a “hold” rating in a research report on Tuesday, March 3rd. Zacks Investment Research upgraded shares of XBiotech from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research report on Saturday, April 11th. BidaskClub upgraded shares of XBiotech from a “sell” rating to a “hold” rating in a research report on Wednesday, June 24th. Finally, Piper Sandler decreased their price objective on shares of XBiotech from $28.00 to $18.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 7th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $20.00.

Shares of XBIT stock opened at $14.35 on Wednesday. The firm has a 50-day moving average price of $14.29 and a 200 day moving average price of $15.71. XBiotech Inc has a twelve month low of $6.84 and a twelve month high of $26.40. The company has a market capitalization of $411.98 million, a price-to-earnings ratio of 0.99 and a beta of 1.44.

XBiotech Company Profile

XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.

Recommended Story: What are benefits of a growth and income fund?

Want to see what other hedge funds are holding XBIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for XBiotech Inc (NASDAQ:XBIT).

Institutional Ownership by Quarter for XBiotech (NASDAQ:XBIT)

Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.